INT207735

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 2.77
Pain Relevance 0.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoskeletal protein binding (TPM1) cytosol (TPM1) cytoskeleton (TPM1)
cytoskeleton organization (TPM1) cytoplasm (TPM1)
Anatomy Link Frequency
stromal cells 2
nerve 1
TPM1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Cancer pain 46 97.12 Very High Very High Very High
Pain 62 96.60 Very High Very High Very High
Nerve growth factor 50 91.32 High High
Lasting pain 6 85.92 High High
allodynia 4 48.76 Quite Low
Hyperalgesia 2 48.32 Quite Low
Breakthrough pain 2 33.28 Quite Low
Thermal hyperalgesia 2 31.28 Quite Low
Inflammation 12 25.84 Quite Low
sodium channel 4 22.92 Low Low
Disease Link Frequency Relevance Heat
Sarcoma 16 99.52 Very High Very High Very High
Cancer 182 99.44 Very High Very High Very High
Neuroma 50 98.20 Very High Very High Very High
Bone Cancer 26 97.32 Very High Very High Very High
Pain 64 96.60 Very High Very High Very High
Cancer Pain 22 93.80 High High
Prostate Cancer 110 93.36 High High
Metastasis 102 86.00 High High
Neuropathic Pain 4 48.76 Quite Low
Hyperalgesia 6 48.32 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The Trk inhibitor (ARRY-470; Array BioPharma, Boulder, CO) is a potent inhibitor of the tropomyosin kinase family of neurotrophin receptors, demonstrating nanomolar cellular inhibition of TrkA (6.5 nM), TrkB (8.1 nM), and TrkC (10.6 nM) and a high level of selectivity over a panel of kinases run at the ATP Km at 1.0 uM and non-kinase receptors [48](Additional file 1 Table S1 and S2).
Negative_regulation (inhibitor) of tropomyosin
1) Confidence 0.57 Published 2010 Journal Mol Pain Section Body Doc Link PMC3004846 Disease Relevance 0.23 Pain Relevance 0.14
Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain

Pain often accompanies cancer and most current therapies for treating cancer pain have significant unwanted side effects.

Negative_regulation (inhibitor) of tropomyosin in nerve associated with pain, sarcoma, cancer pain, cancer, neuroma and bone cancer
2) Confidence 0.42 Published 2010 Journal Mol Pain Section Title Doc Link PMC3004846 Disease Relevance 1.53 Pain Relevance 0.68
Differential expression analysis of the metastatic and primary tumor samples shows that a large number of the most highly downregulated genes such as TAGLN, ACTG2, TPM1, MYH111 and DES have been previously identified as expressed mostly in the prostatic stromal cells [15].
Negative_regulation (downregulated) of TPM1 in stromal cells associated with cancer
3) Confidence 0.25 Published 2007 Journal BMC Cancer Section Body Doc Link PMC1865555 Disease Relevance 0.50 Pain Relevance 0
Differential expression analysis of the metastatic and primary tumor samples shows that a large number of the most highly downregulated genes such as TAGLN, ACTG2, TPM1, MYH111 and DES have been previously identified as expressed mostly in the prostatic stromal cells [15].
Negative_regulation (number) of TPM1 in stromal cells associated with cancer
4) Confidence 0.25 Published 2007 Journal BMC Cancer Section Body Doc Link PMC1865555 Disease Relevance 0.50 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox